tbuckley/cabot-search huggingface dataset:
A phase I study of everolimus (E) plus weekly cisplatin (CDDP) plus intensity-modulated radiation therapy (IMRT) in head and neck (HN) cancer.
Authors: Matthew G. Fury, Eric Jeffrey Sherman, Alan Loh Ho, Shyam S. Rao, Ronglai Shen, Susan H. Korte, Donna M. Lisa, Ian Ganly, Nora Katabi, Snehal G. Patel, Richard J. Wong, Dennis Kraus, Ashok R. Shaha, Jatin P. Shah, Sofia Haque, Nancy Y. Lee, David G. Pfister
Journal: Journal of Clinical Oncology (2012)

5545^ Background: The PI3K/mTOR/eIF4E pathway is upregulated in many HN cancers, and expression of eIF4E in surgical margins has been associated with increased risk of recurrence (Cancer Res 2007; 67:2160. Clin Cancer Res 2004; 10:5820. JCO 1999; 17:2909). Daily E + weekly CDDP was well tolerated in a phase I study for patients with advanced solid tumors (Cancer Chemother Pharmacol 2011 Sep 13; Epub ahead of print]. E achieves radiosensitization in pre-clinical models. This study evaluated weekly CDDP + daily E given concurrently with IMRT in HN cancer. Methods: This was a single institution phase I study with a standard 3 + 3 dose escalation plan. Patients (pts) received standard definitive IMRT (66 Gy resected tumors, 70 Gy unresected tumors) concurrent with CDDP 30 mg/m 2 weekly X 6 and daily oral E according to the dose escalation plan. Four dose levels (DLs) of daily oral E were planned: 2.5 mg, 5 mg, 7.5 mg, and 10 mg. Toxicities were recorded according to NCI CTCAE v.3. Results: Thirteen (9M, 4F) pts enrolled, with median age 52y (range, 37 – 65y) and median KPS 90 (range, 80-100). Primary sites: oral cavity (4), salivary gland (4), oropharynx (2), nasopharynx (1), scalp (1), unknown primary (1). Stage: IVA (11), IVB (1), II (1). Prior treatment: surgery (10), chemotherapy (2). The most common ≥ G.3 treatment related AEs were mucositis (functional 62%, clinical 31%), oral pain (31%), and lymphopenia (31%). There were no DLTs among 3 patients at DL1 or the first 3 patients at DL2. Among 4 pts at DL3, there were 2 DLTs: grade 3 mucositis with failure to thrive, and grade 3 mucositis with hypoxia. Among 3 additional patients enrolled at DL2, there was one 1 DLT: grade 3 mucositis with inability to tolerate E. There were no treatment-related deaths. With a median follow-up of 8.9 months, 3 patients have experienced recurrent disease, one of whom has died of disease. Median PFS has not been reached. Tissue correlates in process. Conclusions: When administered with weekly CDDP (30 mg/m 2 ) and definitive IMRT for HN cancer, the phase II recommended dose of E is 5 mg/day.
Cardiorespiratory fitness and cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer.
Authors: Jingyi Gong, David Payne, Jesse Pittard Caron, Camden Bay, Bradley Alexander McGregor, Jon Hainer, Ann H. Partridge, Tomas G. Neilan, Marcelo Di Carli, Anju Nohria, John Groarke
Journal: Journal of Clinical Oncology (2019)

11576 Background: Androgen deprivation therapy (ADT) plays a pivotal role in management of prostate cancer (PC), with prolonged ADT favored over short-term use in the definitive treatment of high risk PC with radiation. Objectives: To compare cardiorespiratory fitness (CRF) and cardiovascular (CV) mortality among patients with PC with and without ADT exposure, and to explore how duration of ADT exposure influences CRF and CV mortality risk. Methods: This is a retrospective study of patients referred for exercise treadmill testing (ETT) after a diagnosis of PC. PC risk classification was based on Gleason score (GS) at diagnosis: high risk GS ≥ 8, intermediate risk GS= 7, and low risk GS ≤ 6. CRF was categorized according to metabolic equivalents (METs): METs ≥ 8 defined as good CRF and METs &lt; 8 as reduced CRF. ADT exposure was grouped as short-term (≤ 6 months) versus prolonged (&gt; 6 months). Results: 616 patients underwent an ETT a median of 4.8 years (interquartile range: 2.0-7.9) after diagnosis of PC. 150 patients (24.3%) received ADT prior to ETT; 51 with short-term versus 99 with prolonged exposure. 524 (85.1%) patients had ≥ 2 CV risk factors, and 28 CV deaths occurred over 4.2 (interquartile range: 2.3-7.1) years following the ETT. Reduced CRF was more frequent among ADT-exposed versus ADT-naive patients (48.7 versus 32.6%, p&lt; 0.001). Prolonged ADT was associated with reduced CRF (odds ratio (OR): 2.71; 95% confidence interval (CI): 1.31-5.61; p=0.007) and increased CV mortality (hazard ratio (HR): 3.87; 95% CI: 1.16-12.96; p=0.03) in adjusted analyses. In contrast, short-term ADT exposure was not independently associated with either reduced CRF (OR 1.71; 95% CI: 1.00-2.94); p=0.05) or CV mortality (HR: 1.60; 95% CI: 0.51-5.01; p=0.42). Conclusions: Among patients with PC and high baseline CV risk, &gt; 6 months ADT exposure but not less was associated with reduced CRF and increased CV mortality. Reduced CRF may in part mediate increased CV mortality risk. Exercise interventions concurrent with prolonged ADT warrants investigation to potentially offset risk.
Association between intravenous contrast media exposure and non-recovery from dialysis-requiring septic acute kidney injury: a nationwide observational study
Authors: Yoshihisa Miyamoto, Masao Iwagami, Shotaro Aso, Hideo Yasunaga, Hiroki Matsui, Kiyohide Fushimi, Yoshifumi Hamasaki, Masaomi Nangaku, Kent Doi
Journal: Intensive Care Medicine (2019)
Naldemedine for opioid-induced constipation in patients receiving palliative care: A real-world registry study (Phase-R OIC Study).
Authors: Masaki Shimizu, Takaomi Kessoku, Hiroto Ishiki, Tetsuya Matsuura, Yusuke Hiratsuka, Yoshinobu Matsuda, Takaaki Hasegawa, Kengo Imai, Isseki Maeda, Shunsuke Oyamada, Eriko Satomi
Journal: Journal of Clinical Oncology (2019)

11582 Background: Although naldemedine, a new peripherally-acting mu-opioid receptor antagonist, was approved for the management of opioid-induced constipation (OIC), its safety and effectiveness in real world clinical practice is unknown. Methods: We conducted a real world registry study in 14 hospital palliative care teams and inpatient palliative care units in Japan between April and December 2018. Consecutive cancer patients who received naldemedine for OIC were enrolled in a 7-day observational study. All treatment and assessment procedures were performed according to the accepted clinical practice. The primary outcome of the study was the proportion of patients who experienced spontaneous bowel movement within 24 hours after the initial administration of naldemedine. Adverse events, which indicated a possible or stronger causal relationship with naldemedine treatment, were reported according to the Common Terminology Criteria for Adverse Events (CTCAE) ver 4.0. Results: Overall, 204 patients were enrolled in the study. The mean age of the patients was 63±14 years, and 103 (50.5%) were male. The most common primary cancer site was lung (23.5%), followed by gastrointestinal (13.7%), and urological organs (9.3%). The proportion of patients undergoing active cancer treatment was 59.9%. Oxycodone was the most frequently used regular opioid (n = 115, 56.4%), and the median oral morphine-equivalent daily dose of opioids was 30 mg (interquartile range: 20-60 mg). Magnesium oxide (64.2%) and Senna (17.2%) were used as concomitant laxatives. All patients received 0.2 mg of naldemedine orally once daily. Most patients (90.2%) completed the 7-day observation. In 146 patients, spontaneous bowel movement was observed within 24 hour after the first administration of naldemedine (71.6%, 95% confidence interval 65.4-77.8%). Nearly two-thirds of the patients experienced increased frequency of spontaneous bowel movement in the week after naldemedine administration. The most prevalent adverse events were diarrhea (CTCAE grade 1-2, 35 cases; grade 3, 1 case) and abdominal pain (CTCAE grade 1-2, 10 cases; grade 3, 1 case). No serious adverse events including gastrointestinal perforation were reported. Conclusions: Naldemedine for opioid-induced constipation is safe and effective in the real world oncology and palliative care settings. Clinical trial information: UMIN000031381.
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
Authors: Roni Shouval, Joshua A Fein, Myriam Labopin, Nicolaus Kröger, Rafael F Duarte, Peter Bader, Christian Chabannon, Jurgen Kuball, Grzegorz Wladyslaw Basak, Carlo Dufour, Jacques-Emmanuel Galimard, Emmanuelle Polge, Arjan Lankester, Silvia Montoto, John A Snowden, Jan Styczynski, Ibrahim Yakoub-Agha, Mohamad Mohty, Arnon Nagler
Journal: The Lancet Haematology (2019)
Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).
Authors: Mohammad Issam Abu Zaid, Michael T. Milano, Paul C Dinh, Sophie Fosså, Hongmei Yang, Darren R. Feldman, Lois B. Travis, Chunkit Fung
Journal: Journal of Clinical Oncology (2019)

11573 Background: No large, population-based U.S. study has comprehensively examined SMN and HMN risks after TC, taking into account initial therapy and focusing on recent decades. Methods: Standardized incidence ratios (SIR) for SMN and HMN stratified by site and time since TC diagnosis were calculated for 24,900 TCS (median age, TC diagnosis: 33 y) reported to population-based cancer registries in the NCI SEER program (1973-2014). TCS were initially given CHEM (n=6,340), RT (n=9,058), or SURG (n=8,995), with each group accruing 80,700, 156,735, and 128,039 person-years (PY) of follow-up, respectively. Results: During 372,709 PY of follow-up, 1,625 TCS developed SMN and 228 developed HMN, including 107 lymphomas, 92 leukemias, and 29 plasma cell dyscrasias. Among all TCS, overall risk of SMN was increased by 1.06-fold (95% CI 1.01-1.1). Risks of SMN were increased after RT (SIR 1.1, 95% CI 1.06-1.2) and CHEM (SIR 1.3, 95% CI 1.1-1.4); but not after SURG (SIR 0.8). After CHEM, significant excesses of SMN of the pancreas (SIR 2.2), soft tissue (SIR 4.0), kidney (SIR 1.7), thyroid (SIR 3.3) occurred; after RT, significantly elevated risks for SMN of the stomach (SIR 1.7), rectum/sigmoid (SIR 1.4), pancreas (SIR 2.7), soft tissue (SIR 2.2), bladder (SIR 1.5), and thyroid (SIR 2.0) were observed. The 30 year cumulative incidence of SMN after SURG, CHEM, and RT was 8.9% (95% CI 7.8-9.9), 10.1% (95% CI 8.8-11.5) and 17.0% (95% CI 15.8-18.2), respectively. Significantly increased risks of leukemia followed CHEM (SIR 2.7) and SURG (SIR 1.8) and were driven by increased risks for acute myeloid leukemia, with significant excesses restricted to 1-10 y and 1-5 y after TC diagnosis, respectively; nonsignificant 2-fold excesses occurred 1-10 y after RT. Risks for lymphoma and plasma cell dyscrasias were not elevated (1.02 and 1.27, respectively). Conclusions: In the largest population-based study of U.S. TCS to date, we report significant 6% excesses of SMN and 2-fold increased risks of leukemias. Efforts to minimize CHEM exposure and decrease doses/field size of RT in TC should continue. TCS should be educated about cancer prevention and screening.
An analysis of genetic heterogeneity in untreated cancers
Authors: Johannes G. Reiter, Marina Baretti, Jeffrey M. Gerold, Alvin P. Makohon-Moore, Adil Daud, Christine A. Iacobuzio-Donahue, Nilofer S. Azad, Kenneth W. Kinzler, Martin A. Nowak, Bert Vogelstein
Journal: Nature reviews. Cancer (2019)
Appraisal of Cardiac Ejection Fraction With Liver Disease Severity: Implication in Post–Liver Transplantation Mortality
Authors: Hye‐Mee Kwon, Young‐Jin Moon, Kyeo‐Woon Jung, Yong‐Seok Park, Kyoung‐Sun Kim, In‐Gu Jun, Jun‐Gol Song, Gyu‐Sam Hwang
Journal: Hepatology (2019)

Enhanced sympathetic nervous activation and peripheral vasodilation in end-stage liver disease (ESLD) may limit the importance of left ventricular ejection fraction (LVEF) as an influential prognosticator. We sought to understand the LVEF and cardiac dimensions in ESLD patients in order to define the LVEF threshold to predict all-cause mortality after liver transplantation (LT).Data were collected prospectively from the Asan LT Registry between 2008 and 2016, and outcomes were retrospectively reviewed. LVEF, end-diastolic volume index (EDVI), and end-diastolic elastance (Eed) were measured by preoperative echocardiography. Of 2,799 patients, 452 (16.2%) had LVEF ≤ 60%, with 29 (1.0%) having LVEF < 55% and 269 (9.6%) had LVEF ≥ 70%. Over a median of 5.4-year follow-up, 329 (11.8%) patients died: 104 (3.7%) died within 90 days. LVEF (range, 30%-81%) was directly proportionate to Model for End-stage Liver Disease (MELD) scores, an index of liver disease severity, in survivors but showed a fixed flat-line pattern in nonsurvivors (interaction P = 0.004 between groups), with lower EDVI (P = 0.013) and higher Eed (P = 0.001) in the MELD ≥ 20 group. Patients with LVEF ≤ 60% had higher 90-day (13% vs. 7.4%; log rank, P = 0.03) and median 5.4-year (26.7% vs. 16.2%; log rank, P = 0.003) mortality rates in the MELD ≥ 20 group, respectively, compared to those with LVEF > 60%. Specifically, in the MELD > 35 group, median 5.4-year mortality rate was 53.3% in patients with LVEF ≤ 60% versus 24% in those with LVEF > 60% (log rank P < 0.001). By contrast, mortality rates of LVEF ≤ 60% and > 60% were similar in the MELD < 20 group (log rank P = 0.817).LVEF ≤ 60% is strongly associated with higher post-LT mortality rates in the MELD ≥ 20 group, indicating the need to appraise both LVEF and liver disease severity simultaneously. Enhanced diastolic elastance with low EDVI provides insights into pathogenesis of low LVEF in nonsurvivors with MELD ≥ 20.
The attack and defense games
Authors: Roman M. Sheremeta
Journal: Behavioral and Brain Sciences (2019)

The attack-and-defense game is a game in which an attacker (a group of attackers) has an incentive to revise the status quo and a defender (a group of defenders) wants to protect it. The asymmetry in objectives creates incompatible interests and results in a mixed-strategy Nash equilibrium. However, this equilibrium could be heavily impacted by behavioral considerations.
Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients
Authors: Changying Jiang, Shengjian Huang, Yang Liu, Carrie Li, Hui Guo, Jeffrey Wang, Elyse Lopez, Hui Zhang, Elizabeth A Lorence, Maria Merolle, Swathi Balaji, Makhdum Ahmed, Krystle Nomie, Xin Lin, Liang Zhang, Michael Wang
Journal: Blood (2017)
Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?
Authors: Mudit Chowdhary, Akansha Chowdhary, Neilayan Sen, Nicholas George Zaorsky, Kirtesh R. Patel, Dian Wang
Journal: Journal of Clinical Oncology (2019)

11054 Background: Large, high-grade extremity/trunk (ET) non-rhabdomyosarcoma soft-tissue sarcoma (STS) is at high risk for distant recurrence and death. The integration of chemotherapy (C) to standard of care neoadjuvant radiotherapy (RT) remains controversial, even for these patients. This study examines the impact of adding C to neoadjuvant RT on overall survival (OS) in high risk ET-STS. Methods: The National Cancer Data Base (NCDB) was queried for patients ≥18 years with high risk (≥5 cm + high grade) non-rhabdomyosarcoma ET-STS (WHO histology) who received neoadjuvant RT and limb sparing surgery from 2006-2014. Patients were next stratified based upon receipt of C (RT and CRT cohorts). Overall survival (OS) for RT vs CRT cohorts was analyzed using the Kaplan-Meier (KM) method, log-rank test, and Cox proportional hazards models. Propensity score-matched analysis (PSM) was employed to account for potential treatment selection bias between cohorts. Results: A total of 848 (71.1%) and 344 (28.9%) patients received RT and CRT, respectively. Patient cohorts were well-balanced except for the CRT cohort having higher rates of treatment in the West (22.1% vs 10.6%) &amp; Midwest (28.3% vs 22.7%), Charlson-Deyo [CD] score 0 vs ≥1 (85.5% vs 79.4%), younger age (≤50) (45.9% vs 21.7%), synovial sarcoma histology (18.9% vs 3.2%), earlier year of diagnosis (2006-2010) (39.5% vs 32.3%), and positive lymphovascular invasion (2.0 vs 1.51%), (p &lt; 0.05 each). The KM 5-year OS was significantly higher in the CRT vs RT cohort: 69.2% vs 58.1% on univariate (p &lt; 0.0001) and multivariate analysis (Hazard Ratio [HR]: 0.66; 95% Confidence Interval [CI]: 0.52-0.85; p = 0.001) even after adjusting for age, race, income, CD score, histology, tumor size, tumor grade, and primary site (lower extremity; upper extremity; trunk). PSM identified evenly matched cohorts of 300 patients each with respect to age, income, CD score, histology, grade, tumor size, and primary site. The addition of neoadjuvant C remained prognostic for OS on PSM (HR: 0.74 [0.56-0.99], p = 0.042). Conclusions: The addition of C to neoadjuvant RT was associated with improved OS in patients with high risk non-rhabdomyosarcoma ET-STS in the NCDB. These hypothesis generating results support prospective evaluation.
Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy
Authors: GA Salles, J Catalano, P Feugier, FC Offner, R Bouabdallah, D Caballero, P Brice, Lars Møller Pedersen, C Haioun, D Belada, A Delmer, D Simpson, H Tilly, S Leppa, P Soubeyran, A Hagenbeek, O Casasnovas, T Intragumtornchai, C Fermé, M Gomes de Silva, C Sebban, A Lister, JA Esrell, G Milone, A Sonet, A Lopez-Guillermo, JF Seymour
Journal: Blood (2010)
Case 27-2019: A 16-Year-Old Girl with Head Trauma during a Sailboat Race
Authors: Mary A. Iaccarino, Ross D. Zafonte, Emily D. Roy, Magdalena Wojtowicz
Journal: New England Journal of Medicine (2019)

A 16-year-old girl was seen in the sports concussion clinic because of headache, dizziness, balance problems, fatigue, irritability, and difficulties with sleep and concentration after she had head trauma during a sailboat race. A diagnosis and management decisions were made.
Epilepsy. A Study of the Idiopathic Disease.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Position β57 of I-A <sup>g7</sup> controls early anti-insulin responses in NOD mice, linking an MHC susceptibility allele to type 1 diabetes onset
Authors: Louis Gioia, Marie Holt, Anne Costanzo, Siddhartha Sharma, Brian Abe, Lisa Kain, Maki Nakayama, Xiaoxiao Wan, Andrew Su, Clayton Mathews, Yi-Guang Chen, Emil Unanue, Luc Teyton
Journal: Science Immunology (2019)

Onset of type 1 diabetes in NOD mice is triggered by the recognition of I-A g7 insulin peptide complexes by islet CD4 + T cells.
Links Between Childhood Obesity, Gestational Diabetes, and Infant Temperament—Reply
Authors: Myles S. Faith, James B. Hittner, Erica P. Gunderson
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 17942: Oxidative Stress and Apolipoprotein E3 in Brain Endothelial Cells
Authors: Siobanth Cruz, Grace Yomogida, Vasanthy Narayanaswami
Journal: Circulation (2017)

Introduction: Apolipoprotein E3 (apoE3) is an exchangeable protein that plays a significant role as an anti-atherogenic apolipoprotein. It serves as a ligand for the LDL receptor (LDLr) family of p...
One-minute time interval estimation as a novel potent indicator of need for help in cancer patients prior to starting chemotherapy.
Authors: Dragomir Stoyanov, Ivan Donev, Nikolay Vladimirov Conev, Teodorika Panayotova, Martina Ivanova
Journal: Journal of Clinical Oncology (2019)

e23161 Background: Perception of time strongly correlates with people’s current emotional state. Our study explored the potential relationship between the time estimation and the need of help in cancer patients prior to starting chemotherapy. Methods: Time estimation was assessed in 375 chemonaïve patients with solid tumors by evaluating each subject’s prospective estimation of how fast one minute passed compared to the actual time. The median value (40 sec) of time estimation was used to stratify the patients into two categories of fast and slow time estimation. The National Comprehensive Cancer Network Distress Thermometer and Problem List were used at the beginning of treatment to evaluate levels of distress and patients’ concerns. Additional question was asked “Do you need help?”. Results: Patients who reported the need of help were 134 (35.7%). The need of help correlated with fast time estimation, high level of distress and younger age (&lt; 65y). Patients who reported a need of help estimated time significantly faster than those who did not report it (37.2±15.5 vs 42.7±17.2; p = 0.004). ROC analysis revealed that at the optimal cutoff value of time estimation, patients who reported a need of help and those who did not can be discriminated with an AUC = 0.59 (95% CI: 0.53-0.65, p = 0.003) and with a sensitivity of 61.9% and a specificity of 50.6%. Moreover, in a multivariate logistic regression model, fast time estimation was an independent predictor of reporting the need of help (OR 1.59; 95% CI 1.02-2.45; p = 0.04). Conclusions: Time estimation is a novel potent indicator for the need of help in cancer patients. This test is an easily performed, time-saving and nonintrusive ultrashort screening tool for the need of help that is even suitable for patients who are not willing to reveal their need of help via direct questionnaires.